BB&T Corp raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 286,129 shares of the biopharmaceutical company’s stock after buying an additional 3,232 shares during the period. BB&T Corp’s holdings in Gilead Sciences were worth $19,434,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Oregon Public Employees Retirement Fund boosted its stake in shares of Gilead Sciences by 1.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 691,325 shares of the biopharmaceutical company’s stock valued at $46,955,000 after buying an additional 12,600 shares during the period. Parsons Capital Management Inc. RI boosted its stake in shares of Gilead Sciences by 1.6% in the first quarter. Parsons Capital Management Inc. RI now owns 12,310 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 190 shares during the period. Sumitomo Mitsui Asset Management Company LTD boosted its stake in shares of Gilead Sciences by 9.7% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 109,223 shares of the biopharmaceutical company’s stock valued at $7,418,000 after buying an additional 9,654 shares during the period. HealthInvest Partners AB boosted its stake in shares of Gilead Sciences by 3.5% in the first quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock valued at $7,947,000 after buying an additional 4,000 shares during the period. Finally, Dowling & Yahnke LLC boosted its stake in shares of Gilead Sciences by 1.0% in the first quarter. Dowling & Yahnke LLC now owns 48,601 shares of the biopharmaceutical company’s stock valued at $3,301,000 after buying an additional 492 shares during the period. 73.99% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 70.52 on Friday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $88.85. The stock has a market capitalization of $92.15 billion, a price-to-earnings ratio of 7.45 and a beta of 1.20. The firm’s 50 day moving average is $65.46 and its 200 day moving average is $69.00.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.35 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.95%. Gilead Sciences’s payout ratio is 21.99%.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-bbt-corp/1391230.html.

Several brokerages recently weighed in on GILD. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $79.10 target price on the stock. in a report on Monday, March 6th. Mizuho reduced their target price on shares of Gilead Sciences from $88.00 to $77.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Credit Suisse Group reaffirmed a “buy” rating and issued a $79.00 target price on shares of Gilead Sciences in a report on Wednesday, March 1st. Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a report on Thursday. Finally, Deutsche Bank AG began coverage on shares of Gilead Sciences in a report on Friday. They issued a “buy” rating and a $79.00 target price on the stock. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.58.

In other news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $67.48, for a total value of $337,400.00. Following the completion of the transaction, the executive vice president now owns 117,988 shares of the company’s stock, valued at $7,961,830.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Francis Cogan sold 9,943 shares of the stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the transaction, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. In the last three months, insiders sold 88,276 shares of company stock valued at $5,932,578. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.